Inclusion Criteria:  For tumor collection: Age >18, Presumptive diagnosis of primary GBM with plans for surgical resection, Written informed consent to provide tumor and blood and intent to proceed with leukapheresis For randomization: Confirmation of GBM histology, AIVITA Biomedical confirmation of established cancer cell line and sufficient monocytes derived from PBMC during leukapheresis collection, KPS > or = 70, Planning to initiate RT/TMZ, MGMT promotor methylation classified as positive or negative, IDH mutation classified as mutated or wild-type, Written informed consent for randomization and treatment per protocol  Exclusion Criteria:  For tumor collection: Prior history of astrocytoma or other glial tumor, Known autoimmune disease or immunodeficiency, Known previous or current diagnosis of active HBV, HCV or HIV, Diagnosis of any other invasive cancer or disease process considered to be life-threatening within the next 5 years, Known allergy to GM-CSF For randomization: Active infection or other active medical condition that could be life-threatening, Diagnosis of underlying cardiac disease that requires active medical treatment, Pregnant, Enrolled in anotehr investigational trial to receive an investigational treatment, KPS < 70, Did not meet inclusion/exclusion criteria for tumor collection